{
  "id": "clinical#general_425c5e47",
  "content": "hypocretin deficiency: In this rare subtype (less than 5% of nar-\ncolepsy cases), Criterion B requirements of cataplexy and posi-\ntive polysomnography/multiple sleep latency test are met, but\nCSF hypocretin-1 levels are normal (Criterion B2 not met).\n347.00 (G47.419) Autosomal dominant cerebellar ataxia,\ndeafness, and narcolepsy: This subtype is caused by exon 21\nDNA (cytosine-5)-methyltransferase-1 mutations and is charac-\nterized by late-onset (age 30–40 years) narcolepsy (with low or\nintermediate CSF hypocretin-1 levels), deafness, cerebellar ataxia,\nand eventually dementia.\n347.00 (G47.419) Autosomal dominant narcolepsy, obesity,\nand type 2 diabetes: Narcolepsy, obesity, and type 2 diabetes\nand low CSF hypocretin-1 levels have been described in rare\ncases and are associated with a mutation in the myelin oligoden-\ndrocyte glycoprotein gene.\n347.10 (G47.429) Narcolepsy secondary to another medical\ncondition: This subtype is for narcolepsy that develops second-\nary to medical conditions that cause infectious (e.g., Whipple’s\ndisease, sarcoidosis), traumatic, or tumoral destruction of hypo-\ncretin neurons.\nCoding note (for ICD-9-CM code 347.10 only): Code first\nthe underlying medical condition (e.g., 040.2 Whipple’s dis-\nease; 347.10 narcolepsy secondary to Whipple’s disease).\nSpecify current severity:\nMild: Infrequent cataplexy (less than once per week), need for",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "sleep"
    ],
    "is_clinical": false,
    "is_advice": false
  },
  "index_text": "General — General hypocretin deficiency: In this rare subtype (less than 5% of nar-\ncolepsy cases), Criterion B requirements of cataplexy and posi-\ntive polysomnography/multiple sleep latency test are met, but\nCSF hypocretin-1 levels are normal (Criterion B2 not met).\n347.00 (G47.419) Autosomal dominant cerebellar ataxia,\ndeafness, and narcolepsy: This subtype is caused by exon 21\nDNA (cytosine-5)-methyltransferase-1 mutations and is charac-\nterized by late-onset (age 30–40 years) narcolepsy (with low or\nintermediate CSF hypocretin-1 levels), deafness, cerebellar ataxia,\nand eventually dementia.\n347.00 (G47.419) Autosomal dominant narcolepsy, obesity,\nand type 2 diabetes: Narcolepsy, obesity, and type 2 diabetes\nand low CSF hypocretin-1 levels have been described in rare\ncases and are associated with a mutation in the myelin oligoden-\ndrocyte glycoprotein gene.\n347.10 (G47.429) Narcolepsy secondary to another medical\ncondition: This subtype is for narcolepsy that develops second-\nary to medical conditions that cause infectious (e.g., Whipple’s\ndisease, sarcoidosis), traumatic, or tumoral destruction of hypo-\ncretin neurons.\nCoding note (for ICD-9-CM code 347.10 only): Code first\nthe underlying medical condition (e.g., 040.2 Whipple’s dis-\nease; 347.10 narcolepsy secondary to Whipple’s disease).\nSpecify current severity:\nMild: Infrequent cataplexy (less than once per week), need for Hypocretin deficiency: in this rare subtype (less than 5% of nar-\ncolepsy cases), criterion b requirements of cataplexy and posi-\ntive polysomnography/multiple giấc ngủ latency test are met, but\ncsf hypocretin-1 levels a..."
}